Myeloid leukemias express a broad spectrum of VEGF receptors including neuropilin-1 (NRP-1) and NRP-2

Vascular endothelial growth factor (VEGF) is produced in neoplastic cells in various myeloid neoplasms and may act as an autocrine growth-regulator. We have examined the expression of five VEGF receptors (VEGR1/Flt-1, VEGFR2/KDR, Flt-4, neuropilin-1 = NRP-1, NRP-2) in leukemic cells obtained from patients with acute myeloid leukemia (n = 28), chronic myeloid leukemia (n = 14), chronic eosinophilic leukemia (n = 3), chronic myelomonocytic leukemia (n = 9), or mast cell leukemia/systemic mastocytosis (n = 3) as well as in respective cell lines. Expression of VEGFR mRNA was analyzed by RT-PCR, and expression of VEGFR protein by immunocytochemistry. In most patients, leukemic cells expressed NRP-1 mRNA and NRP-2 mRNA independent of the type of disease. By contrast, transcripts for Flt-1, KDR, and Flt-4 were expressed variably without a clear correlation to the type of leukemia. Expression of VEGF receptors was also demonstrable at the protein level in all cases tested. In conclusion, neoplastic cells in myeloid leukemias frequently express VEGFR including NRP-1 and NRP-2.

[1]  M. Kreuter,et al.  Correlation of neuropilin-1 overexpression to survival in acute myeloid leukemia , 2006, Leukemia.

[2]  D. Printz,et al.  Enumeration and immunohistochemical characterisation of bone marrow basophils in myeloproliferative disorders using the basophil specific monoclonal antibody 2D7 , 2006, Journal of Clinical Pathology.

[3]  P. Valent,et al.  Immunohistochemical detection of vascular endothelial growth factor (VEGF) in the bone marrow in patients with myelodysplastic syndromes: correlation between VEGF expression and the FAB category , 2006, Leukemia & lymphoma.

[4]  R. Hehlmann,et al.  Chronic myeloid leukemia: a model for oncology , 2005, Annals of Hematology.

[5]  C. Marosi,et al.  Identification of mTOR as a novel bifunctional target in chronic myeloid leukemia: dissection of growth‐inhibitory and VEGF‐suppressive effects of rapamycin in leukemic cells , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[6]  J. Gribben,et al.  The role of the tumor microenvironment in hematological malignancies and implication for therapy. , 2005, Frontiers in bioscience : a journal and virtual library.

[7]  D. Hicklin,et al.  Inhibition of Both the Autocrine and the Paracrine Growth of Human Leukemia with a Fully Human Antibody Directed Against Vascular Endothelial Growth Factor Receptor 2 , 2004, Leukemia & lymphoma.

[8]  J. Herbert,et al.  VEGF‐R2 and neuropilin‐1 are involved in VEGF‐A‐induced differentiation of human bone marrow progenitor cells , 2004, Journal of cellular physiology.

[9]  E. Beierle,et al.  Expression of VEGF receptors in cocultured neuroblastoma cells. , 2004, The Journal of surgical research.

[10]  S. Dias,et al.  Internal and external autocrine VEGF/KDR loops regulate survival of subsets of acute leukemia through distinct signaling pathways. , 2004, Blood.

[11]  B. Schneeweiss,et al.  Immunohistochemical detection of VEGF in the bone marrow of patients with chronic myeloid leukemia and correlation with the phase of disease. , 2004, American journal of clinical pathology.

[12]  J. Bennett.  The myelodysplastic/myeloproliferative disorders: the interface. , 2003, Hematology/oncology clinics of North America.

[13]  B. Longley,et al.  Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. , 2003, Experimental hematology.

[14]  H. Kantarjian,et al.  Clinical relevance of VEGF receptors 1 and 2 in patients with chronic myelogenous leukemia. , 2003, Leukemia research.

[15]  N. Ferrara,et al.  The biology of VEGF and its receptors , 2003, Nature Medicine.

[16]  Christian Sillaber,et al.  Immunohistochemical detection of VEGF in the bone marrow of patients with acute myeloid leukemia. Correlation between VEGF expression and the FAB category. , 2003, American journal of clinical pathology.

[17]  J. Griffin,et al.  Mutated tyrosine kinases as therapeutic targets in myeloid leukemias. , 2003, Advances in experimental medicine and biology.

[18]  D. Gilliland,et al.  Genetics of myeloid leukemias. , 2003, Annual review of genomics and human genetics.

[19]  S. Soker,et al.  In vivo administration of vascular endothelial growth factor (VEGF) and its antagonist, soluble neuropilin-1, predicts a role of VEGF in the progression of acute myeloid leukemia in vivo. , 2002, Blood.

[20]  Christian Sillaber,et al.  BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. , 2002, Blood.

[21]  E. Estey,et al.  Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes , 2002, Cancer.

[22]  A. Chott,et al.  Increased angiogenesis in the bone marrow of patients with systemic mastocytosis. , 2002, The American journal of pathology.

[23]  D. Hossfeld.  E.S. Jaffe, N.L. Harris, H. Stein, J.W. Vardiman (eds). World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues , 2002 .

[24]  H. Zwierzina,et al.  Blood levels of angiogenin and vascular endothelial growth factor are elevated in myelodysplastic syndromes and in acute myeloid leukemia. , 2002, Journal of hematotherapy & stem cell research.

[25]  E. Berg,et al.  World Health Organization Classification of Tumours , 2002 .

[26]  H. Kantarjian,et al.  Acute myeloid leukemia , 2018, Methods in Molecular Biology.

[27]  S. Rafii,et al.  Inhibition of both paracrine and autocrine VEGF/ VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[28]  L. Shaw,et al.  Advances in Brief Vascular Endothelial Growth Factor Is an Autocrine Survival Factor for Neuropilin-expressing Breast Carcinoma Cells 1 , 2001 .

[29]  P. Valent,et al.  Mutation analysis of C‐KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis , 2001, British journal of haematology.

[30]  E. Estey.  Prognostic factors in acute myelogenous leukemia , 2001, Leukemia.

[31]  T. Grogan,et al.  Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. , 2001, Blood.

[32]  I. Zachary,et al.  Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. , 2001, Cardiovascular research.

[33]  G. Martiny-Baron,et al.  Donor stromal cells from human blood engraft in NOD/SCID mice. , 2000, Blood.

[34]  J. Melo,et al.  The molecular biology of chronic myeloid leukemia. , 2000, Blood.

[35]  E. Estey,et al.  Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. , 2000, Blood.

[36]  M. Caligiuri,et al.  Core-binding factor (CBF) and MLL-associated primary acute myeloid leukemia: biology and clinical implications , 1999, Annals of Hematology.

[37]  T. Grogan,et al.  Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. , 1999, Cancer research.

[38]  J. Pouysségur,et al.  p42/p44 MAP Kinase Module Plays a Key Role in the Transcriptional Regulation of the Vascular Endothelial Growth Factor Gene in Fibroblasts* , 1998, The Journal of Biological Chemistry.

[39]  S. Ergün,et al.  Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. , 1997, Blood.

[40]  A. Mantovani,et al.  Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. , 1996, Blood.

[41]  Y. Suzuki,et al.  Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[42]  D. Rosenthal,et al.  Chronic myelomonocytic leukemia. , 1990, Leukemia.

[43]  H. Gralnick,et al.  Proposals for the Classification of the Acute Leukaemias French‐American‐British (FAB) Co‐operative Group , 1976, British journal of haematology.

[44]  J. B. Chatterjea,et al.  Chronic myelogenous leukaemia , 1973, Indian journal of pediatrics.